Revolutionizing Medicine through Pharmacogenomics

Phone: (919) 465-0100 |


Thank You for Visiting Gentris, A CGI Company

Gentris Corporation entered into an agreement with Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, by which Cancer Genetics acquired Gentris on June 30, 2014.

Due to CGI’s world-class knowledge on genomic of cancer and Gentris’ expertise on understanding drugs effectiveness based on germline DNA, we expect the combined entity to deliver biopharma companies with critical genomic information that will increase clinical trial success rates and lower drug development costs.

Together, we are delivering the promise of precision medicine.

Learn more about our integrated solutions for clinical trials.